

SPECIAL TOPIC

Advancing Immune and Cell-Based Therapies Through Imaging

Vladimir Ponomarev 

Department of Radiology, Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Ave Z-2063, Box 501, New York, NY, 10065, USA

Abstract

Immunotherapies include various approaches, ranging from stimulating effector mechanisms to counteracting inhibitory and suppressive mechanisms, and creating a forum for discussing the most effective means of advancing these therapies through imaging is the focus of the newly formed Imaging in Cellular and Immune Therapies (ICIT) interest group within the World Molecular Imaging Society. Efforts are being made in the identification and validation of predictive biomarkers for a number of immunotherapies. Without predictive biomarkers, a considerable number of patients may receive treatments that have no chance of offering a benefit. This will reflect poorly on the field of immunotherapy and will yield false hopes in patients while at the same time contributing to significant cost to the healthcare system. This review summarizes the main strategies in cancer immune and cell-based therapies and discusses recent advances in imaging strategies aimed to improve cancer immunotherapy outcomes.

Key words: Cell-based therapy, Imaging, Immunotherapy

Introduction

Recently, immuno-based therapies have been found to provide lasting and curative benefits to patients who have previously had very few treatment options available to them. These immunotherapeutic approaches thereby have the potential to revolutionize cancer therapy and become an important part of comprehensive therapeutic approaches for treating many diseases including cancer. These therapies build on the primary function of the immune system to rid the body of threats, both “foreign”, such as bacterial and viral pathogens and “domestic”, such as cancer cells. Over the past several decades of cancer immunology research, there has been evidence that tumor cells are recognized by the native or genetically engineered adoptive immunity, but also that tumors can modify these responses and escape immune recognition [1]. Immune modulation in cancer treatment, therefore, refers to a range of approaches aimed at harnessing and enhancing the patient’s immune system and overcoming immune escape, to achieve tumor control, stabilization, and potential eradication of

disease. This has led to the development of therapies that permit specific tumor destruction with minimal toxicity to normal tissue [2–6]. Such strategies also have the potential to prevent tumor recurrence because of the immune systems long-term memory. Within the World Molecular Imaging Society, we have constituted an interest group comprised of members of the society who share the common interest of fostering the use of imaging to advance and understand cellular and immune-based therapies. This Interest Group is called Imaging in Cellular and Immune Therapies (ICIT), and we present here a brief summary of the field and our efforts in the society to support developments in this important area of investigation.

Current Advances in Immune and Cell Therapies

The main categories of immunotherapies being developed include monoclonal antibodies, recombinant cytokines, cancer-specific, and other types of vaccines and adoptive immune cell transfer [3, 7, 8]. Several immunotherapies have been approved by the Food and Drug Administration (FDA), and others are

Correspondence to: Vladimir Ponomarev; e-mail: ponomarv@mskcc.org

being evaluated in pre-clinical and clinical trials. The field of immunotherapy for cancer has received a significant boost by the approval of several immunotherapies. These include immunostimulatory cytokines for the treatment of cancer, viral hepatitis and osteopetrosis (*e.g.*, IL-2 [9], interferons [10, 11]). The autologous cellular vaccine, sipuleucel-T, has also recently been approved for the treatment of prostate cancer [12]. Perhaps the immunotherapies that have received the most attention are the immune checkpoint inhibitors that overcome immune escape. These target the anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) and the anti-programmed cell death protein/protein ligand 1 (anti-PD-1/PD-L1) with antibodies and are being used for the treatment of melanoma, lung cancer, renal cell carcinoma and head and neck tumors [13–16]. Other forms of immunotherapy including administration of *ex vivo* expanded tumor infiltrating lymphocytes (TILs), transgenic endogenous T cell receptor (TCR)- or chimeric antigen receptor (CAR)-grafted T cells have been successfully tested in clinical trials in patients with melanoma, B cell malignancies, mesothelioma, ovarian and prostate cancers and will likely get FDA approval in the near future [17–23]. This emerging collection of immune-based therapeutic approaches hold great promise for the treatment of cancer, but are also being adopted for many non-malignant conditions such as autoimmunity, infectious diseases, and immunodeficiencies [24–26].

At the moment, immunotherapy with checkpoint inhibitors provide a foundation for many of the combinatorial strategies [27] as it allows for enhancing an immune response against multiple cancers including tumors expressing weak antigens [28]. However, one of the main obstacles to the development of a successful immunotherapeutic approach is in identification and *in vivo* assessment of the most suitable antigen(s) to use. Molecular imaging reagents that target specific cancer antigens can help selecting patients that will likely respond to antigen-directed immunotherapies and will allow for early response assessment and prediction of treatment outcome by visualizing antigen distribution preceding tumor targeting with radioimmunotherapy, drug-immunoconjugates, or antigen-specific T lymphocytes [29–33].

Imaging as an Outcome Measure

A vital component of any cancer treatment is the objective assessment and monitoring of tumor response to anticancer therapy using imaging and specific response evaluation criteria. The response evaluation criteria in solid tumors (RECIST) was proposed in 2000, and this criterion is anatomic in nature and specifies the number of disease sites and their dynamics as the imaging metric for determining response (*e.g.*, complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD)) [34]. However, clinical experience suggests that RECIST may be inadequate to cover the spectrum of imaging responses to immunotherapy since the determinants of increase in tumor size and/or the appearance of new lesions that often suggest treatment failure, might not be entirely applicable here. As observed in multiple studies, immunotherapy often demonstrates initial anatomical imaging changes that would be classified as

disease progression, followed by radiological and clinical response suggesting therapeutic response [35, 36].

As immunotherapies continue to be developed and undergo testing in clinical trials, consideration needs to be given to the unique appearance of images that predict tumor responses. Such studies have found four distinct response patterns on imaging, all of which were associated with favorable survival: (a) shrinkage of baseline lesions without new lesions, which is consistent with RECIST; (b) durable SD followed by a slow, steady decline in total tumor burden in some patients; (c) response after initial increase in total tumor burden; and (d) response in the presence of new lesions [37–39]. These updated immune-related response criteria (IrRC) are defined as a way to incorporate imaging patterns observed with immunotherapy into the response assessment criteria including metabolic response to treatment assessed by 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) and positron emission tomography (PET) [40]. One of the aims of the ICIT Interest Group is to verify and validate these measures over a range of immune-based therapies, and to continue to develop new measures as new tools and technologies are developed for both treating and imaging cancer.

Imaging Biomarkers

One of the challenges of immunotherapy is that accurate and reproducible biomarkers that would allow treating physicians to select the patients most likely to respond have yet to be identified, vetted, and deployed. The potential of molecular imaging to detect these biomarkers and better stratify the patients for targeted therapies and interpreting their response to this novel treatment option cannot be overestimated. Currently, there is no single robust biomarker to identify the patients who will most likely benefit from these treatments, and as we advance precision medicine, it is likely that panels of biomarkers will be required for guiding therapy and assessing outcome. For example, PD-L1 expression levels have been suggested as a positive prognostic biomarker for patients undergoing immune checkpoint blockade therapy [41]. Following pathology-derived data, a number of PD-L1-specific radiotracers were developed that allowed for non-invasive assessment of tumor PD-L1 status in murine models, with the intent of predicting the efficacy of PD-1 checkpoint blockade [42–45]. However, studies have demonstrated the lack of clinical benefit in some patients treated with anti-PD-1 antibodies despite positive PD-L1 status of their tumors [46, 47]. Therefore, the levels of PD-L1 within the tumor microenvironment cannot, at present, be considered an optimal biomarker for patient selection until we can better reveal and understand the basic biology and mechanisms of action of check-point blockade.

There are certain challenges with [¹⁸F]FDG and [¹⁸F]FLT PET avidity as biomarkers in assessment of the efficacy of immunotherapy that include the difficulty of discriminating between viable tumor and the infectious or inflammatory processes associated with novel therapies [48, 49]. A number of new radiopharmaceuticals have been proposed and evaluated in pre-clinical and clinical studies aiming to distinguish rapidly proliferating immune cells invading the




Fig. 1 Anti-CD8 immuno-PET in subcutaneous colorectal immunotherapy model. CT26 murine colon cancer-grafted mice were treated with CD137-agonistic Abs: CD137-treated, CD137-treated/CD8-blocked mice, and control mice (no anti-CD137 therapy) were injected with 89Zr-malDFO-169 cDb and immuno-PET images were acquired at 22 h postinjection. Note the presence of increased CD8+ tumor-infiltrating lymphocytes within the tumor in CD137-treated animal (*white arrow*, adapted from [56]).

tumor or involved in any type of immune response. Several ¹⁸F-labeled nucleoside analogs, including 1-(2'-Deoxy-2'-[¹⁸F]fluoroarabino-furanosyl)cytosine (aka [¹⁸F]FAC) [50, 51], 2-chloro-2'-deoxy-2'-[(18)F]fluoro-9-β-d-arabino-furanosyl-adenine (aka [¹⁸F]CFA) [52, 53], and 2'-deoxy-2'-[¹⁸F]fluoro-9-β-D-arabino-furanosyl-guanine (aka [¹⁸F]AraG) [54] that are specific for key enzymes involved in T lymphocyte and other immune cell activation and proliferation, have been used for detecting location of activated T cells, monitoring transplant rejection, and graft-versus-host-disease and diagnosis and staging of auto-immune disorders. These new radiotracers can be early

predictors of response and adverse reactions to immunotherapy measuring functional status of immune cells involved.

Another imaging approach that can directly visualize immune cells behavior is immuno-PET. In this approach, antibodies or antibody fragments are used to direct PET radionuclides to immune cells for detection, localization and typing. Immuno-PET has the potential to detect T cell subsets within tumors or lymphoid tissues and noninvasively monitor distribution and temporal dynamics of CD8 cytotoxic and CD4 helper T lymphocytes that participate in the inflammation and cytotoxic attack within tumors. Anti-CD8 full size antibodies and mini-bodies labeled with Cu-64, Zr-89, F-18, or I-124 showed excellent PET imaging and target specificity and importantly did not deplete CD8 T cells due to the absence of Fc function (Fig. 1) [55, 56]. Other targets include markers of immunostimulatory dendritic cells (MHC II, IDO1), chemokine ligands, and receptors (CXCR3,-4, CXCL9,-12 CCR5) as well as immunosuppressive neutrophils and macrophages (CD11b, CD47), which may downregulate T cell responses within tumors [57–61]. Examples of immuno-imaging targets and agents are summarized in Table 1.

Imaging of Immune Cells

Recent advances in the field of adoptive immunotherapy require the ability to monitor the trafficking, targeting, and activation/proliferation of the administered cells. The application of labeling molecules and genetic reporter systems (gene/probe combinations) together with non-invasive imaging modalities, such as PET, SPECT, and MRI, has shown the potential for monitoring T cells in clinical settings [67–69]. In-111, in particular, found a wide clinical application in oncology as an imaging agent for monitoring immunotherapy with tumor-infiltrating lymphocytes and granulocytes administration [70, 71]. However, imaging approaches that require *ex vivo* cell labeling encompass a number of limitations such as radiotoxicity and limited period of monitoring as a result of cell division, biological clearance and radiolabel decay [72, 73].

Table 1. Immuno-imaging targets and agents

Immune cell compartment/function	Molecular target	Imaging agent	Modality	Stage of development
Tumor/Tumor immunosuppressive microenvironment	PD-L1	[⁸⁹ Zr]/[⁶⁴ Cu]Anti-PD-L1-Ab/peptide [43–45] ([⁸⁹ Zr]MPDL3280A) [NCT02453984]	PET	Clinical
Immune cell proliferation	Deoxycytidine kinase	L-[¹⁸ F]FAC, -CFA [51, 53]	PET	Clinical
T lymphocyte activation	Deoxyguanosine kinase	[¹⁸ F]AraG [54]	PET	Clinical
Cytotoxic T lymphocytes	CD8	[⁸⁹ Zr]/[⁶⁴ Cu]Anti-CD8-Ab [55, 56] ([⁸⁹ Zr]IAB22M2C)	PET	Clinical
Macrophages	N/A	Ferumoxytol [62]	MRI	Clinical
T lymphocyte inhibition	CTLA-4	[⁶⁴ Cu]Anti-CTLA-4-Ab [63]	PET	Pre-clinical
T lymphocyte inhibition	PD-1	[⁶⁴ Cu]Anti-PD-1-Ab [45]	PET	Pre-clinical
Macrophages (TAMs)	CD47	[⁸⁹ Zr]Anti-CD47-Ab [58]	PET	Pre-clinical
Neutrophils	CD11b/MHC-II	[¹⁸ F]/[⁶⁴ Cu]Anti-CD11b/MHC-II-Ab [57]	PET	Pre-clinical
Transgenic T cells	Transgenic TCR	[⁸⁹ Zr]/[⁶⁴ Cu]Anti-TCR-Ab [64, 65]	PET	Pre-clinical
T lymphocyte trafficking	CXCR4	[⁶⁴ Cu]AMD3100 [60]	PET	Pre-clinical
Macrophages (TAMs)	B7-H3	MicrobubblesAnti-B7-H3 [66]	Ultrasound	Pre-clinical

N/A not available

Stable genetic labeling of adoptively transferred cells with reporter genes (genes encoding easily detectable proteins not normally expressed by the cells) has been used to circumvent the temporal limitations of *ex vivo* radiolabeling. Several reporter gene/reporter probe combinations have been used in the majority of the seminal studies on imaging immune cell trafficking including *ex vivo* expanded cytotoxic lymphocytes (CTLs) and CAR-grafted T cells by optical and nuclear techniques (e.g., luciferases, fluorescent proteins, HSV1tk, respectively [67, 68, 74–79]) including imaging in humans (Fig. 2) [80]. In addition, reporter gene imaging allows for visualization of T lymphocyte functional status following T cell receptor engagement by using inducible reporter systems sensitive to T cell activation [81]. This circumstance makes this imaging approach clinically valuable, as it allows for monitoring functional status of adoptively transferred immune cells in cancer patients as well as in bone marrow and stem cell recipients. The major impediment to the translation of viral- and bacterial-derived reporter gene imaging approaches into clinical practice is the immunogenicity of these non-human derived reporter proteins. However, there has been a recent focus on human reporter systems to avoid the potential risk of generating an immunological reaction to xenogeneic (non-human) reporter proteins thus allowing for long-term repetitive




Fig. 2 Tumor-directed CAR-T cell PET imaging with $[^{18}\text{F}]\text{FHBG}$. $[^{18}\text{F}]\text{FHBG}$ PET imaging was performed in a patient with a recurrent right frontoparietal glioblastoma **a** before and **b** 1 week after tumor-specific CAR-T cell infusions. Allogeneic CAR-T cells and IL-2 were injected intratumorally (red arrows). Tumor recurrence was monitored by T₁-weighted (T₁W) MRI (top panels). $[^{18}\text{F}]\text{FHBG}$ PET images were fused with MR images (bottom panels), and three-dimensional (3D) volumes of interest were drawn using a 50 % $[^{18}\text{F}]\text{FHBG}$ SUV_{max} threshold, outlined in yellow (adapted from [80]).

visualization of adoptively transferred immune cells. These include human-derived sodium iodide symporter (hNIS), norepinephrine transporter (hNET), somatostatin receptor 2 (hSSTR2), truncated, and mutated mitochondrial thymidine kinase type 2 (hΔTK2, hΔTK2DM) and deoxycytidine kinase (hdCKDM, hdCK3M), ferritin reporter, and transferrin receptor [82–89]. Some reporter genes may have the added benefit of suicide gene potential. This provides a mechanism for elimination of rogue reporter gene-expressing immune cells with clinically approved chemo- and radiotherapeutics (e.g., HSV1tk/ganciclovir, hdCKDM/gemcitabine, hNIS/I-131, hNET/ $[^{131}\text{I}]\text{MIBG}$ [90–93]).

Principles of immuno-PET can be applied to imaging adoptively transferred cells by administering anti-antigen-specific transgenic TCR radiolabeled antibodies. Antigen-specific TCR transgenic T cells were successfully visualized with PET using ^{89}Zr -89 labeled anti-TCRμ-F(ab')₂ fragment [64] and $[^{64}\text{Cu}]\text{DOTA}$ -modified cOVA-TCR-specific mAbs [65].

The potential of imaging for quantifying cell signals in a region of anatomical interest (ROI) provides a unique opportunity to estimate the absolute number of injected labeled cells at the target site. Several studies determined the correlation of PET signal to cell number and characterized the cellular limit of detection for PET imaging using human and mouse T cells transduced with different human and non-human reporters with a limit of detection below 10^5 cells in a region of interest of 0.1 ml volume [85, 87, 94]. This level of sensitivity enables effective assessment of cell localization at target sites and assessment of off target homing *in vivo* and will be useful in guiding development of novel immune therapies.

Conclusion

As immunotherapies continue to be developed and undergo testing in clinical trials, consideration needs to be given to the differences observed in response following immunotherapy, and as a community, we need to standardize these measures and ensure uniformity among studies. While optimal combinations of treatment schemas still need to be determined, significant efforts have to be made in the identification and validation of predictive biomarkers that can be used alone or in combination in imaging, but also in conjunction with blood and tissue markers *ex vivo*. It is imperative that we as a community of imaging scientists interested in immunotherapy be proactive in advancing this field.

Compliance with Ethical Standards

Conflict of Interest

The author declares that he has no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Whiteside TL, Demaria S, Rodriguez-Ruiz ME et al (2016) Emerging opportunities and challenges in cancer immunotherapy. *Clin Cancer Res* 22:1845–1855
2. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 369:122–133
3. Menon S, Shin S, Dy G (2016) Advances in cancer immunotherapy in solid tumors. *Cancers (Basel)* 8: doi:10.3390/cancers8120106.
4. Geyer MB, Brentjens RJ (2016) Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. *Cytotherapy* 18:1393–1409
5. D'Souza NM, Fang P, Logan J et al (2016) Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies. *Front Oncol* 6:212
6. Hughes PE, Caenepeel S, Wu LC (2016) Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. *Trends Immunol* 37:462–476
7. Kandalaft LE, Powell DJ, Singh N, Coukos G (2011) Immunotherapy for ovarian cancer: what's next? *J Clin Oncol* 29:925–933
8. Sabado RL, Balan S, Bhardwaj N (2017) Dendritic cell-based immunotherapy. *Cell Res* 27:74–95
9. Millet A, Martin AR, Ronco C et al (2017) Metastatic melanoma: insights into the evolution of the treatments and future challenges. *Med Res Rev* 37:98–148
10. Hayes CN, Chayama K (2017) Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses. *J Med Virol* 89:388–396
11. Razaghi A, Owens L, Heimann K (2016) Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation. *J Biotechnol* 240:48–60
12. Hu R, George DJ, Zhang T (2016) What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. *Ther Adv Urol* 8:272–278
13. Hodi FS, Chesney J, Pavlick AC et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol* 17:1558–1568
14. Du L, Herbst RS, Morgensztern D Immunotherapy in lung cancer. *Hematol Oncol Clin North Am* 31:131–141
15. Donin NM, Lenis AT, Holden A et al (2017) Immunotherapy for the treatment of Urothelial carcinoma. *J Urol* 197:14–22
16. Msaouel P, Massarelli E (2016) Immune checkpoint therapy in head and neck cancers. *Cancer J* 22:108–116
17. Sadelain M (2016) Chimeric antigen receptors: driving immunology towards synthetic biology. *Curr Opin Immunol* 41:68–76
18. Johnson LA, June CH (2017) Driving gene-engineered T cell immunotherapy of cancer. *Cell Res* 27:38–58
19. Yang JC, Rosenberg SA (2016) Adoptive T-cell therapy for cancer. *Adv Immunol* 130:279–294
20. Anurathapan U, Leen AM, Brenner MK, Vera JF (2014) Engineered T cells for cancer treatment. *Cytotherapy* 16:713–733
21. Park JH, Geyer MB, Brentjens RJ (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. *Blood* 127:3312–3320
22. Koneru M, O'Ceirbhail R, Pendharkar S et al (2015) A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. *J Transl Med* 13:102
23. Morello A, Sadelain M, Adusumilli PS (2016) Mesothelin-targeted CARs: driving T cells to solid tumors. *Cancer Discov* 6:133–146
24. Northrup L, Christopher MA, Sullivan BP, Berkland C (2016) Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity. *Adv Drug Deliv Rev* 98:86–98
25. Tashiro H, Brenner MK (2017) Immunotherapy against cancer-related viruses. *Cell Res* 27:59–73
26. McLaughlin LP, Bollard CM, Keller M (2017) Adoptive T cell immunotherapy for patients with primary immunodeficiency disorders. *Curr Allergy Asthma Rep* 17:3
27. Vilgelm AE, Johnson DB, Richmond A (2016) Combinatorial approach to cancer immunotherapy: strength in numbers. *J Leukoc Biol* 100:275–290
28. Desrichard A, Snyder A, Chan TA (2016) Cancer neoantigens and applications for immunotherapy. *Clin Cancer Res* 22:807–812
29. Haberkorn U, Eder M, Kopka K et al (2016) New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. *Clin Cancer Res* 22:9–15
30. Sharma SK, Sevak KK, Monette S et al (2016) Preclinical 89Zr immuno-PET of high-grade serous ovarian cancer and lymph node metastasis. *J Nucl Med* 57:771–776
31. Pandit-Taskar N, O'Donoghue JA, Durack JC et al (2015) A phase I/II study for analytic validation of 89Zr-J591 ImmunoPET as a molecular imaging agent for metastatic prostate cancer. *Clin Cancer Res* 21:5277–5285
32. Rylova SN, Del Pozzo L, Klingeberg C et al (2016) Immuno-PET imaging of CD30-positive lymphoma using 89Zr-Desferrioxamine-labeled CD30-specific AC-10 antibody. *J Nucl Med* 57:96–102
33. Kramer K, Kushner BH, Modak S et al (2010) Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. *J Neuro-Oncol* 97:409–418
34. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada *J Natl Cancer Inst* 92: 205–216.
35. Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 369:134–144
36. Li XD, Ji M, Zheng X et al (2014) Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors. *J Transl Med* 12:215
37. Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 15:7412–7420
38. Khoja L, Kibiro M, Metser U et al (2016) Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. *Br J Cancer* 115:1186–1192
39. Nishino M (2016) Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment. *J Immunother* 4:30
40. Braschi-Amirfarzan M, Tirumani SH, Hodi FS Jr, Nishino M (2017) Immune-checkpoint inhibitors in the era of precision medicine: what radiologists should know. *Korean J Radiol* 18:42–53
41. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. *Mol Cancer Ther* 14:847–856
42. Mayer AT, Natarajan A, Gordon S et al (2016) Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. *J Nucl Med*. doi:10.2967/jnumed.116.177659
43. Chatterjee S, Lesniak WG, Miller MS et al (2017) Rapid PD-L1 detection in tumors with PET using a highly specific peptide. *Biochem Biophys Res Commun* 483:258–263
44. Lesniak WG, Chatterjee S, Gabrielson M et al (2016) PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET. *Bioconjug Chem* 27:2103–2110
45. Hettich M, Braun F, Bartholomä MA et al (2016) High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. *Theranostics* 6:1629–1640
46. Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. *Lancet Oncol* 17:e542–e551
47. Wang X, Teng F, Kong K, Jinming Y (2016) PD-L1 expression in human cancers and its association with clinical outcomes. *Onco Targets Ther* 9:5023–5039
48. van Waarde A, Elsinga PH (2008) Proliferation markers for the differential diagnosis of tumor and inflammation. *Curr Pharm Des* 14:3326–3339
49. Basu S, Kumar R, Alavi A (2010) PET and PET-CT imaging in infection and inflammation: its critical role in assessing complications related to therapeutic interventions in patients with cancer. *Indian J Cancer* 47:371–379
50. Nair-Gill E, Wiltzius SM, Wei XX et al (2010) PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. *J Clin Invest* 120:2005–2015
51. Schwarzenberg J, Radu CG, Benz M et al (2011) Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. *Eur J Nucl Med Mol Imaging* 38:711–721

52. Kim W, Le TM, Wei L et al (2016) [¹⁸F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. *Proc Natl Acad Sci U S A* 113:4027–4032
53. Barrio M, Spick C, Radu CG et al (2016) Human biodistribution and radiation dosimetry of 18F-CFA, a PET probe targeting the deoxyribonucleoside salvage pathway. *J Nucl Med*. doi:10.2967/jnumed.116.182394
54. Namavari M, Chang YF, Kusler B et al (2011) Synthesis of 2'-deoxy-2'-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. *Mol Imaging Biol* 13:812–818
55. Tavare R, McCracken MN, Zettlitz KA et al (2014) Engineered antibody fragments for immunopET imaging of endogenous CD8+ T cells *in vivo*. *Proc Natl Acad Sci U S A* 111:1108–1113
56. Tavare R, Escuin-Ordinas H, Mok S et al (2016) An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. *Cancer Res* 76:73–82
57. Rashidian M, Keliher EJ, Bilate AM et al (2015) Noninvasive imaging of immune responses. *Proc Natl Acad Sci U S A* 112:6146–6151
58. Zheleznyak A, Ikotun OF, Dimitry J et al (2013) Imaging of CD47 expression in xenograft and allograft tumor models. *Mol Imaging* 12:1–10
59. Xie L, Maeda J, Kumata K, et al. (2015) Development of 1-N-(11)C-Methyl-L- and -D-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan. *Sci Rep* 5: doi:10.1038/srep16417
60. Nimmagadda S, Pullambhatla M, Stone K et al (2010) Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [⁶⁴Cu]AMD3100 positron emission tomography. *Cancer Res* 70:3935–3944
61. Luehmann HP, Pressly ED, Detering L et al (2014) PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. *J Nucl Med* 55:629–634
62. Schmitz SA, Taupitz M, Wagner S et al (2001) Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. *J Magn Reson Imaging* 14:355–61
63. Higashikawa K, Yagi K, Watanabe K et al (2014) ⁶⁴Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. *PLoS One* 9:109866
64. Mall S, Yusufi N, Wagner R et al (2016) Immuno-PET imaging of engineered human T cells in tumors. *Cancer Res* 76:4113–4123
65. Griessinger CM, Mauer A, Kesenheimer C et al (2015) ⁶⁴Cu antibody-targeting of the T-cell receptor and subsequent internalization enables *in vivo* tracking of lymphocytes by PET. *Proc Natl Acad Sci U S A* 112:1161–1166
66. Bachawal SV, Jensen KC, Wilson KE et al (2015) Breast cancer detection by B7-H3-targeted ultrasound molecular imaging. *Cancer Res* 75:2501-9
67. Koehne G, Doubrovin M, Doubrovina E et al (2003) Serial *in vivo* imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. *Nat Biotechnol* 21:405–413
68. Dubey P, Su H, Adonai N et al (2003) Quantitative imaging of the T cell antitumor response by positron-emission tomography. *Proc Natl Acad Sci U S A* 100:1232–1237
69. Kircher MF, Allport JR, Graves EE et al (2003) *In vivo* high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. *Cancer Res* 63(20):6838–6846
70. Thakur ML, Seifert CL, Madsen MT et al (1984) Neutrophil labeling: problems and pitfalls. *Semin Nucl Med* 14:107–117
71. Fisher B, Packard BS, Read EJ et al (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. *J Clin Oncol* 7:250–261
72. Kircher MF, Gambhir SS, Grimm J (2011) Noninvasive cell-tracking methods. *Nat Rev Clin Oncol* 8:677–688
73. Zanzonico P, Koehne G, Gallardo HF et al (2006) [¹³¹I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. *Eur J Nucl Med Mol Imaging* 33:988–997
74. Hardy J, Edinger M, Bachmann MH et al (2001) Bioluminescence imaging of lymphocyte trafficking *in vivo*. *Exp Hematol* 29:1353–1360
75. Stephan MT, Ponomarev V, Brentjens RJ et al (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. *Nat Med* 13:1440–1449
76. Dobrenkov K, Olszewska M, Likar Y et al (2008) Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. *J Nucl Med* 49:1162–1170
77. Kim Y, Dubey P, Ray P et al (2004) Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a trifusion reporter gene. *Mol Imaging Biol* 6:331–340
78. Dotti G, Tian M, Savoldo B et al (2009) Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with ¹⁸F-FEAU. *Mol Imaging* 8:230–237
79. Singh H, Najjar AM, Olivares S et al (2009) PET imaging of T cells derived from umbilical cord blood. *Leukemia* 23:620–622
80. Keu KV, Witney TH, Yaghoubi S, et al. (2017) Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. *Sci Transl Med* 9. DOI: 10.1126/scitranslmed.aag2196
81. Ponomarev V, Doubrovin M, Lyddane C et al (2001) Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography *in vivo*. *Neoplasia* 3:480–488
82. Likar Y, Zurita J, Dobrenkov K et al (2010) A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. *J Nucl Med* 51:1395–1403
83. Vedvyas Y, Shevlin E, Zaman M et al (2016) Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. *JCI Insight* 1:e90064
84. McCracken MN, Vatakis DN, Dixit D et al (2015) Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. *J Clin Invest* 125:1815–1826
85. Moroz MA, Zhang H, Lee J et al (2015) Comparative analysis of T cell imaging with human nuclear reporter genes. *J Nucl Med* 56:1055–1060
86. Campbell DO, Yaghoubi SS, Su Y et al (2012) Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. *J Biol Chem* 287:446–454
87. Doubrovin MM, Doubrovina ES, Zanzonico P et al (2007) *In vivo* imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. *Cancer Res* 67:11959–11969
88. Gilad AA, Winnard PT, van Zijl P, Bulte JWF (2007) Developing MR reporter genes: promises and pitfalls. *NMR Biomed* 20:275–290
89. Vandsburger MH, Radoul M, Cohen B, Neeman M (2013) MRI reporter genes: applications for imaging of cell survival, proliferation, migration and differentiation. *NMR Biomed* 26:872–884
90. Greco R, Oliveira G, Stanghellini MTL, et al. (2015) Improving the safety of cell therapy with the TK-suicide gene. *Front Pharmacol* 6: doi:10.3389/fphar.2015.00095
91. Lee JT, Zhang H, Moroz MA et al (2017) Comparative analysis of human nucleoside kinase-based reporter systems for PET imaging. *Mol Imaging Biol* 19:100–108
92. Kim YH, Youn H, Na J et al (2015) Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene. *Theranostics* 5:86–96
93. Streby KA, Shah N, Ranalli MA et al (2015) Nothing but NET: a review of norepinephrine transporter expression and efficacy of ¹³¹I-mIBG therapy. *Pediatr Blood Cancer* 62:5–11
94. Su H, Forbes A, Gambhir SS, Braun J (2004) Quantitation of cell number by a positron emission tomography reporter gene strategy. *Mol Imaging Biol* 6:139–148